Sweden
Calmark Sweden AB is a biotechnology and health care startup based in Sweden. Founded in 2007, the company's slogan "Caring for a calm start" reflects its mission to improve the healthcare journey for newborns. Calmark specializes in providing patient-near tests (PNA) specifically tailored for newborns to rapidly understand their health status, thereby enhancing the entire healthcare chain, reducing waiting times and costs, particularly in regions lacking hospital laboratories.
The company's innovative test platform, comprising a portable instrument and test cartridges for various biomarkers, aims to provide simpler and swifter analyses of medical conditions in newborns. The market launch of its first test, Neo-Bilirubin, commenced in 2020. Calmark's introduction of PNA tests in developed healthcare systems leads to substantial cost savings and shorter healthcare chains, while in less developed healthcare systems, its product addresses the lack of access to hospital laboratories, filling a crucial diagnostic support gap.
Calmark aspires to be the global leader, offering all relevant tests for newborns, irrespective of their birth location. Additionally, the company is developing a PNA test for assessing the severity of COVID-19. Notably, its B-aktien is listed on the Spotlight Stock Market and trades under the name CALMA B.
The company's last investment was a Venture Round investment on 31 October 2011 from Almi Invest. With its focus on revolutionizing newborn healthcare and its strategic expansion into COVID-19 diagnosis, Calmark presents an intriguing opportunity for potential investors seeking innovation within the healthcare and biotechnology sectors. To learn more, visit www.calmark.se.
